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Novelty and Impact  
This is the first study that empirically obtained utility scores for quality of life associated 
with cervical cancer screening and treatment in women in all relevant health states, ranging 
from being invited for screening to being disease-free after primary treatment of cervical 
cancer or having advanced cancer. Furthermore, we show that quality of life assumptions 
determine the cost-effectiveness of cervical cancer screening and that the measure used to 
empirically assess utilities is crucial for cost-effectiveness conclusions. 
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ABSTRACT  
Quality adjusted life years are used in cost-effectiveness analyses (CEAs). To calculate 
QALYs, a ‘utility’ (0-1) is used for each health state induced or prevented by the 
intervention. We aimed to estimate the impact of quality-of-life (QoL) assumptions (utilities 
and durations of health states) on CEAs of cervical cancer screening. To do so, twelve 
alternative sets of utility assumptions were retrieved from published cervical cancer 
screening CEAs. Two additional sets were based on empirical QoL data that were integrally 
obtained through two different measures (SF-6D and EQ-5D) from eight groups of women 
(total n= 3,087), from invitation for screening to diagnosis with cervical cancer. Per utility 
set we calculated the number of quality-adjusted days lost (QADL) for each relevant health 
state in cervical cancer screening, by multiplying the study-specific assumed disutilities (i.e. 
1-utility) with study-specific durations of the loss in QoL, resulting in 14 ‘QADL-sets’. With 
microsimulation model MISCAN we calculated cost-effectiveness of 342 alternative 
screening programs (varying in primary screening test [Human Papillomavirus (HPV) versus 
cytology], starting ages, and screening interval) for each of the 14 QADL-sets. Utilities used 
in CEAs appeared to differ largely. We found that ten QADL-sets from the literature resulted 
in HPV and two in cytology as preferred primary test. The SF-6D empirical QADL-set resulted 
in cytology and the EQ-5D one in HPV as preferred primary test. In conclusion, assumed 
utilities and health state durations determine cost-effectiveness of cervical cancer 
screening. Also, the measure used to empirically assess utilities can be crucial for CEA 
conclusions.   
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INTRODUCTION 
Cervical cancer screening, still widely based on cytological Pap test, decreases mortality and 
incidence from this cancer.1 However, changes are ongoing in cervical cancer prevention, 
such as the introduction of human papilloma virus (HPV) screening and HPV vaccination 
programs. An important criterion for appraising the validity of a new screening programme 
is that its benefit (i.e. preventing clinical cancer and cancer death) should outweigh its 
physical, psychological, and societal harm (caused by the test and screening-related 
diagnostic procedures and treatment).2 This is assessed in a cost-effectiveness analysis 
(CEA). CEAs can use ‘quality adjusted life years’ (QALYs) as the summary effect measure. 
The QALY is a generic effect variable of disease burden, including both the quality and the 
length of life lived.3 To calculate QALYs, a quality-adjustment weight or ‘utility’ is applied to 
each relevant health state. A utility is a number anchored at 0 (dead) and 1 (perfect health), 
indicating the preferability of that health state in terms of quality of life. Because of their 
crucial impact on CEAs, and thus on health care decision making about the introduction of 
e.g. screening programs or the choice about specific screening tests, reliable estimates of 
the utility scores of all health states induced and prevented by screening are important.  
For cervical cancer screening, after early detection via cytological abnormalities, women 
with cervical intraepithelial neoplasia (CIN) can be treated so that potential development of 
these abnormalities into cancer is prevented. The downsides of cervical cancer screening 
are lack of specificity, overdiagnosis and overtreatment, since most of the abnormalities 
found in the screening and follow up will never develop into clinical cervical cancer. 
Notably, it was shown that in the Netherlands one prevented cervical cancer death due to 
screening entails an estimated 2,097 women being screened, 64 women being sent to 
triage, and 42 women being referred for colposcopy, with punch biopsy and eventually 
treatment of mostly preinvasive neoplastic conditions.4  The numbers of women needed to 
be screened or sent to triage or colposcopy to prevent one cervical cancer death increase by 
implementation of a more sensitive (but less specific) screening test. Recently it was shown, 
that the implementation of primary HPV screening in the Netherlands may lead to a 
threefold increase in the number of (false-positive) referrals to the gynaecologist.5 Women 
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screened and referred to a gynaecologist may experience distress and anxiety.6-8 Per 
woman this may have a limited effect, but considering the large numbers of women 
screened and referred, small quality of life losses for these harms might still result in 
relevant effects at population level. We currently lack empirically derived utility estimates 
for all relevant health states in cervical cancer screening. Currently, available utility 
estimates in the literature are conflicting, which results in parameter uncertainty.9 
 
The present study first aims to estimate the impact of the variation in currently used sets of 
utility assumptions on the estimated cost-effectiveness of cervical cancer screening 
programs. To do so, we will review utility assumptions in the CEA literature. Next, we will 
use microsimulation modelling to estimate the impact of the differences in utility 
assumptions on the cost-effectiveness of cervical cancer screening (in a population 
unvaccinated against HPV) and on the preferred screening strategies.  
Second, we derived two sets of utilities based on a state of the art empirical study. In this 
study, we have performed an integrated questionnaire study addressing all states related to 
the cervical cancer-screening programme in a generic and standardized way, resulting in 
two types of utilities for all relevant health states. Selected parts of this empirical study 
have been published earlier 6, 10-12 The study results will be presented here as a whole. Next, 
we will evaluate how use of our empirical utility measurements affects the microsimulation 
cost-effectiveness results, and how this compares to using utility estimates applied in the 
cervical cancer screening CEA literature. 
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METHODS 
Part 1: Literature review 
To collect the utilities that have been used so far, we reviewed the literature for CEAs of 
cervical cancer screening published between 2003 and 2015. We used the following search 
terms in Pubmed: cost-benefit analysis; cost-effectiveness analysis; uterine cervical 
neoplasms; cervical cancer; screening; early detection of cancer; quality-adjusted life years; 
QALY. We selected papers that examined cost-effectiveness of screening from Europe, 
North-America and Australia that are published in English. We identified 19 studies that 
used QALYs.4, 13-30 Two pairs of studies used the same set of utility assumptions (i.e. same 
model and research group), and each of these pairs were combined (4and 29; 17 and 18). One 
study was excluded since it also used a common set of utility assumptions that was already 
included.23 One study was excluded since the utilities used were not reported.25 The 
resulting 15 studies defined different health states in cervical cancer screening. We first 
summarized the published health states into 13 health states (primary screening; positive 
primary screentest; false positive test; referral for triage test; referral for colposcopy; false 
positive referral; CIN1; CIN2; CIN3; FIGO 1; FIGO2+; Survivors; Palliative phase). We then for 
each study assessed the number of days lost due to diminished QoL (‘quality-adjusted days 
lost’ (QADL)) for these different health states, by multiplying the study-specific assumed 
disutilities (i.e. 1-utility) with the study-specific mean durations of the loss (or gain) in QoL. 
Three studies20, 28, 30 were excluded because of absence of data on the durations. For five 
studies4, 16, 24, 26, 27 we had to make assumptions (based on limited available information) on 
durations (see footnotes Table 2). So, the literature review resulted in 12 different ‘QADL-
sets’. Appendix Table 3 shows the assumed utilities in the twelve included published CEAs 
per health stage, as well as the source of each of the assumed utilities.  
 
Part 2: Questionnaire study 
We empirically obtained utility scores, indicating quality of life, for 7 study groups of 
women: invited for cervical cancer screening (n=1,023 respondents, of whom 905 
participated in screening, response 60%); having borderline or mildly dyskaryotic (BMD) pap 
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test results (n=270; response 49%); referred for colposcopy (n=132); treated for a precursor 
of cervical cancer (n=81; response 49%); diagnosed with cervical cancer (n=77); disease-free 
after primary treatment of cervical cancer (n=285; response 69%), and a reference group 
(n=835, response 46%, Appendix Table 2). The methods and results have been published in 
detail for the EQ-5D scores of the screening participants,10 the group with borderline or 
mildly dyskaryotic pap test results,6 women referred for colposcopy,12 and women who are 
disease-free after treatment.11 Data were collected by self-administered questionnaires, 
containing both the EQ-5D and SF-6D questions. At the time of data-collection HPV 
screening had not been introduced yet. A description of the data-collection procedures and 
the background characteristics of the participants is included in the Appendix (Appendix 
Tables 1 and 2). No women with advanced cervical cancer (i.e. palliative phase) could be 
included due to logistic reasons; for this group we used utility estimates of women with 
breast or lung cancer.31, 32 The ethics review committee of Erasmus University Medical 
Center Rotterdam approved the research protocol.  
 
Utility measures 
A quality-adjustment weight or ‘utility’ is a number anchored at 0 and 1, with “perfect 
health” carrying a weight of 1 and dead carrying a weight of 0. We used both the SF-6D and 
the EQ-5D. The SF-6D, based on a subset of SF-12 responses,33 is composed of six 
dimensions: physical functioning, role limitations, social functioning, bodily pain, mental 
health, and vitality. It was derived from a valuation study among a representative sample of 
the general public in the UK, using the standard gamble valuation technique.33 The EQ-5D 
classification consists of five dimensions: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression.34 Response categories indicate 1) no problems; 2) 
some problems; or 3) serious problems. Responses were linked to utility scores as obtained 
in the UK using time trade-off methodology.34Information on age, marital status, education, 
and profession of respondents was obtained through the questionnaires.  
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Statistical analyses 
Paired t-tests were used to assess the statistical significance of differences between SF-6D 
and EQ-5D scores. Pearson product-moment correlations were used to calculate within-
person correlations between SF-6D and EQ-5D assessments. All analyses were performed in 
SPSS, version 20. 
 
Calculation of quality adjusted days lost (QADL) 
Based on the questionnaire study we calculated the number of QADL for those health states 
for which we empirically found a significant different utility (measured by the EQ-5D and 
the SF-6D, separately) compared to the reference population (screening ages in case of 
screening health states and all ages in case of cancer health states). For these health states 
we calculated the disutility by subtracting the measured utility (the point estimate) in that 
specific health state from the utility measured in the general population (screening ages in 
case of screening stages).  In case of ‘terminal care’ we subtracted the utility in breast 
cancer patients in the last year of life from the utility in the general population, both 
measured by the EQ-5D. We then calculated the number of QADL for the different health 
states, by multiplying the measured disutilities with the durations of the loss in QoL per 
state. The durations where based on 1) the Dutch screening guideline in case of a BMD 
result (i.e. 15 months), 2) measured duration of significant QoL loss in case of longitudinal 
measurements for referral to the gynaecologist and cancer health states, 3) 10 years in case 
of cancer survivor based on the definition used in the questionnaire study, 4) last year of life 
in case of terminal care (i.e. 1 year). 
 
Part 3: Microsimulation modelling 
We used the microsimulation screening analysis (MISCAN) model29  to estimate the costs 
and QALYs gained for alternative cervical cancer screening programs, in a Dutch 
(unvaccinated against HPV) population. The model and the inputs used are described in the 
Appendix, as well as in an earlier publication.29 Also, the calibration and validation of the 
model are described in an online technical appendix [http://hdl.handle.net/1765/31582]. 
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We simulated 1,000,000 unvaccinated women born between 1939 and 1992. The 
alternative strategies included primary cytology and primary HPV (followed by cytology 
triage) screening, with respective triage strategies that according to the MISCAN model 
used were cost-effective.29 We considered all screening policies with starting ages of 25, 27, 
30 or 32 years that comprise at least three and at most ten screenings in a woman’s 
lifetime. Policies had an interval of at least three years and at most ten years, policies that 
include screenings over the age of 70 years were excluded. This resulted in 342 simulated 
screening policies. Based on monitoring (program), trial and administrative (program and 
hospital) data we made assumptions on screening attendance, test characteristics and costs 
(see Appendix Table 4). The sensitivity of the HPV test (the probability of a positive test 
result if an HPV infection is present) was estimated at 94%, and the sensitivity of cytology 
was assumed to be 40% for CIN 1, 50% for CIN 2, and 75% for CIN 3 and invasive cervical 
cancer (see Appendix Table 4). The specificity of the HPV test (probability of a negative test 
for women without high-risk HPV infections) is assumed to be 100%, and the specificity of 
cytology (probability of a negative test for women without CIN or cancer) is estimated to be 
98.5%. Lack of specificity in case of HPV screening was accounted for by the inclusion of 
fast-clearing HPV infections. 
The lifelong costs and effects of each simulated screening program were counted for the 
period from 2011 onwards (until all women have died), and discounted at an annual rate of 
3% towards the year 2011. For each woman, we calculated the number of QALYs as the 
weighted sum of the number of years spent in each of the health states, using the state 
specific utility weights. The total effectiveness of screening (QALYs gained) is determined as 
the difference in the number of QALYs between the situation with screening and the 
situation without screening. We used a similar approach to determine the net costs of 
screening. 
Programs that were more costly and less effective than other programs were ruled out as 
non-efficient (by both simple and extended dominance). The remaining programs constitute 
the frontier of efficient screening programs, see the lines in Figure 2. For each ‘QADL-set’ 
we determined which screening programs were located on the cost-effectiveness frontier. 
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Based on the incremental cost-effectiveness ratios (ICERs) between these programs we 
determined which screening program was preferred considering cost-effectiveness 
thresholds of €20,000 and €50,000 per QALY gained. 
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RESULTS 
Part 1: Literature review 
Both for screening and treatment phases we found a large variation in number of QADL 
between the published studies (Table 1). For example, the number of QADL for a cervical 
intraepithelial neoplasia (CIN) 2 or CIN 3 lesions varied from 0 to 47.5. For a FIGO 
(International Federation of Gynecology and Obstetrics) stage 2+ cancer, the number of 
QADL varied from 51 to 1460, which is an 80-fold difference. This variation is the result of 
differences in utility values (see Appendix Table 3), as well as differences in durations. We 
found that all CEAs ultimately refer to 12 different original utility studies, published 
between 1991 and 2012 (see Appendix Table 4). 
 
Part 2: Questionnaire study  
SF-6D utility scores 
The mean utility score was 0.83 (confidence interval (CI): 0.82-0.84) in the general adult 
female population and 0.84 (CI: 0.83-0.85) in the on average somewhat younger women in 
screening ages (30-60 years), see Table 2 and Figure 1A. Screen participants’ mean scores 
were slightly higher: 0.85 before and after screening and 0.86 after receiving the test 
results. The mean utility of women who were recommended to have a repeat Pap test 
because of borderline or mild dyskaryotic test results were lower than those of the 
reference population and the screening invitees. Before onset of treatment, both FIGO 
groups reported similar utility scores. The FIGO 1 group (n=47) improved steadily from 0.73 
at baseline to 0.81 one year later, while the FIGO 2+ group (n=16) reported 0.71 at baseline, 
0.63 at three months follow-up, and 0.71 and 0.75 at six and twelve months follow-up. The 
mean utility of tumorfree cancer survivors was 0.80, and thus comparable to that of women 
with cervical cancer FIGO 1 at 1-year post –diagnosis. 
Overall, SF-6D utility scores were best (0.86, CI: 0.85-0.87) in screen participants after 
receipt of Pap test results and worst in women with cervical cancer (FIGO 2+) at three 
months after diagnosis (0.63, CI:0.57-0.70).  
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Comparison of SF-6D and EQ-5D utility scores  
SF-6D and EQ-5D utility scores were always significantly correlated and the patterns of SF-
6D and EQ-5D utility scores were roughly similar (Figures 1.A and 1.B). On average, SF-6D 
utility scores were lower than EQ-5D utility scores, but in more serious health states, such 
as diagnosis with cervical cancer, SF-6D and EQ-5D scores no longer significantly differed. 
 
Number of QADL  
The number of QADL based on our questionnaire study differ substantially from those used 
in the CEAs obtained from the literature. The QADL, calculated with the SF-6D, due to 
having gone through a triage episode is 14 days. With the EQ-5D, no significant different 
utility was measured for women in triage compared to the references population (screening 
ages) (Table 2), so no QADL were measured in the screening stages. The QADL (SF-6D) due 
to a FIGO2+ cancer diagnosis is 161 (51+110) days for survivors and 234 (51+183) days for 
those who die from it (Table 2). In case of the EQ-5D, these figures are 166 (21+146) and 
204 (21+183), respectively. 
 
Part 3: Microsimulation modelling 
Per ‘QADL-set’ different screening programs are presented on the cost-efficient frontier 
(Figure 2). Table 3 shows per QADL-set the preferred screening strategy at cost-
effectiveness thresholds of €20,000 and €50,000 per QALY gained, according to the MISCAN 
model. At a willingness to pay of €20,000 per QALY, eleven QADL-sets (ten from the 
literature and the EQ-5D empirical data) preferred HPV screening, all starting at age 30 or 
32, performing 3 or 4 tests with a 5 or 6 year interval. Our empirical SF-6D data and two 
other sets from the literature preferred cytology screening, starting at age 30 or 32, 
performing 4 or 5 tests at a 4, 5 or 6 year interval. 
At €50,000 per QALY, the optimal strategies tended to have lower starting ages (age 27 to 
30), with more tests (7 to 10) and shorter intervals (4 to 6 years). However, the preferred 
screening tests for each QADL-set did not change. The QADL-set ‘Kitchener (Simonella)’22 
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resulted in less frequent screening, since this set showed a considerable loss in QoL related 
to attending screening.  
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DISCUSSION 
We showed that differences in quality of life assumptions as they are found in published 
cervical cancer screening CEAs and as measured in an integral questionnaire study using 
utility measures, lead to different conclusions about cost-effectiveness of strategies. 
Differences in quality of life assumptions result in different number of QALYs gained for the 
same screening strategy and, as a result, different ICERs between screening strategies. In 
general, it largely depends on utility losses assumed for positive screening results including 
the associated follow up, which screening modality is preferred. Primary HPV screening, 
with relatively more positive screen test results than cytology screening, is preferred in case 
of lower utility loss assumptions for the screening phase (used in ten studies), and cytology 
in case of higher utility losses (used in two studies). For example, the assumed number of 
QADL due to referral in the study of Karnon et al. 24 is significantly higher than in the other 
scenarios, and therefore having a (false-positive/clinically not relevant) referral for 
colposcopy has more impact in this scenario than in the other scenarios. In this example, 
one could argue that the fact that a large majority of studies used lower utility losses in the 
screening phases, provides some strong certainty that HPV screening is to be preferred. In a 
situation with high uncertainty, however, such counting of studies not necessarily leads to 
the correct conclusions. Clearly, focussing further screening related QoL research on follow 
up after positive screen results is important.  
The use of the presented empirical utility data measured by the SF-6D resulted in the 
preference for primary cytology screening, whereas in most utility sets used in the CEA 
literature, primary HPV screening was preferred. This was caused by the fact that relatively 
larger quality of life losses were found with the SF-6D for triage and referral for colposcopy, 
which is a health state that will occur more frequently with primary HPV screening than 
with cytology.35 As a result, more quality of life will be lost due to the screening itself with 
primary HPV screening compared to cytology and therefore primary cytology becomes the 
preferred strategy.  Our finding that quality of life assumptions influence the results of CEA 
of cervical cancer prevention is in line with previous studies.22, 36, 37  
14 
We found large differences in utility estimates and durations used in CEAs. It appeared that 
none of these CEAs was based on utility estimates derived from empirical data of cervical 
cancer screenees or actual patients who were faced with the studied diagnosis in real life, 
but on data collected in other (patient) groups (i.e. patients with other conditions than 
(precursors of) cervical cancer). However, patients (that experience the studied disease) 
often report better quality of life than healthy people who are asked to imagine the 
patient’s circumstances; the so-called disability paradox.38 Causes of this paradox include 
loss aversion, focusing illusion, and underestimation of their own adaptation in healthy 
people and adaptation processes in patients.39-41 These phenomena indicate the importance 
of empirically derived utility estimates.  
In this first study to empirically assess the QoL effects of all relevant stages in population-
based organized cervical cancer screening, we observed, per woman involved, only limited 
QoL loss due to screening as long as there was no diagnosis of cervical cancer. This held for 
women invited for screening, referred for colposcopy, and treated for a CIN lesion. A study 
on the impact of abnormal cervical smear results found that at baseline, shortly after the 
news, women who had received abnormal results reported significantly worse overall 
quality of life (EQ-5D and SF-6D) than women with normal results. At 12 weeks follow-up, 
only SF-6D results still significantly differed between groups. The QALYs lost during the 16 
weeks after being informed of an abnormal smear result were estimated to be 0.007–0.009, 
which is equivalent to 2.4 to 3.2 days of healthy life lost.42 Studies that focused on 
condition-specific effects like anxiety and worry did report negative effects of screen-
detected non-cancer abnormalities.6, 12, 42-44 Our findings may thus be related to the use of 
generic measures, which are less sensitive to small, condition-specific changes in health or 
quality of life. The patterns of the two generic measures used (EQ-5D and SF-6D) were 
roughly similar, although EQ-5D utility scores were often significantly higher than SF-6D 
scores. This is in line with the literature.45 With different items and scoring mechanisms, the 
EQ-5D and the SF-6D were not expected to generate completely similar utilities. However, 
the EQ-5D and the SF-6D each resulted in a different preferred screening strategy, which 
clearly shows the dependence of CEA results on the choice of generic measure.  
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Limitations and strengths 
With regard to the questionnaire study, we acknowledge that some of the (sub) groups 
were of limited size, that response rates are unavailable for the data collection among 
women referred for colposcopy and women diagnosed with cervical cancer, and that data 
considering the final stages of life were collected among patients with primary breast or 
lung cancer, and not among patients with cervical cancer. Also, we reported SF-6D as based 
on responses to the SF-12 items although SF-6D is better able to discriminate between 
conditions if based on responses to the SF-36 items.46 Furthermore, screening has some rare 
undesired effects, like pregnancy complications after treatment for CIN, which were not 
captured in this study, but are important to be mentioned.47 Also, we acknowledge that we 
assessed utilities in the Netherlands, and that we cannot determine if and to which extent 
this has influenced our results. However, we used widely accepted measures, that are each 
available in over 170 languages and that have been applied in numerous studies. We 
conclude that we have not solved all issues of how to determine the impact of cervical 
cancer on quality of life. However, at least we now have an idea about extent of the 
implications of screening and treatment for quality of life. We provided a set of empirical 
data and we do think that such a set is vital for the validity of CEAs. This data was collected 
in one country and we recommend more international data-collection to study external 
validity. Since we do not know what the results will be in another setting, we recommend to 
use the utilities as collected in the current study in modelling exercises, at least as an extra 
dataset, to enable sensitivity analyses. Still, this is the first study that made the extensive 
effort of comprising all health states induced or prevented by screening on cervical cancer. 
Data were collected in 7 cohorts, of which three were followed longitudinally. An additional 
strength is that the available clinical information enabled subdividing respondent groups 
according to FIGO stage. The design of our study has proven its feasibility and value, and 
can serve as a basis for measurements in other populations and situations. 
This is also the first study focusing on the impact of utility assumptions on the 
recommended cervical cancer screening strategy. We, however, only used one model (for 
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the Dutch situation) to estimate the impact. Also, in absence of utility measurements for 
being HPV positive, we had to make the assumption that the effect on quality of life is 
similar for having a positive cytology test compared to having a positive HPV test. If higher 
quality of life losses will be found for being HPV positive than cytology positive, HPV 
screening might be less cost-effective than indicated by our calculations. Furthermore, in 
case of the HPV test, we assumed similar sensitivity for all disease stages with an HPV 
infection. Recent studies indicated lower sensitivity of HPV screening in women without any 
neoplasia.48 We, however, calibrated our model to the observed HPV positivity rate 
(measured with a clinical validated HPV test) in the Dutch population, which determines the 
effect of HPV screening in the population. If we assume a lower sensitivity, we would have 
to increase the number of infections in the model, to reproduce that HPV positivity rate. 
Finally, the literature included in our analyses is not an exhaustive summary. We, for 
example, did not include HPV vaccination CEAs, even if vaccination was applied in a 
screening setting. Since the information on utility assumptions and the durations of the 
health states was sometimes lacking in the publications, we had to do some approximations 
to calculate the QADL. But even if our assumptions differ from the assumptions in the 
specific publications, our study clearly shows the importance of the utility assumptions for 
preferred cervical cancer screening strategies. We used the example of cervical cancer 
screening, but think the central message of our findings is generalizable to other settings, 
such as other (cancer) screening programs and vaccination programs. 
 
Implications 
The ongoing changes in cervical cancer prevention, such as the introduction of HPV 
screening and HPV vaccination programs require new policy, which is nowadays 
unacceptable without CEAs. The empirical utility scores that now have become available will 
enable more valid estimates of cost-effectiveness of screening programs and will contribute 
to a better evidence base for policy recommendations, which is especially useful given 
limited resources. Our results also showed that measuring utility values for different health 
states in screening is feasible but challenging, because these often involve small, condition-
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specific changes in quality of life. This indicates that in economic evaluations, besides the 
QALY, other measurements that include the harms and benefits of screening (such as, 
number needed to screen or number needed to treat) need to be regarded as well.  
 
Conclusion 
This is the first study that empirically estimated utilities for the majority of the cervical 
cancer health states. We found that QoL assumptions in decision analyses vary in a range 
that is crucial for preferences regarding screening strategies. Empirical data show that 
primary HPV screening might not be the most cost-effective screening strategy, if QALYs are 
used in this decision. However, the empirical data also show that the measurement of 
utilities is challenging. This indicates that other measurements that include the harms and 
benefits of screening needs to be regarded as well. 
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Table 1. Number of quality adjusted days lost (QADL) (utility loss x duration in days)  found in published CEAs and empirical data per 
health state. Publications with unknown durations of health states are excluded. 20, 28, 30  
 
Source 
Induced by screening: screening and pre-invasive health states Prevented by screening: invasive cancer health states 
Prim. 
screens 
Pos. 
prim. 
screens 
False-
pos. 
prim. 
screens 
Triage 
tests 
Referrals 
for 
colposcopy 
False-
pos. 
Referral 
CIN1 CIN2 CIN3 FIGO 1 FIGO 2+ Palliative 
phase 
Survivors 
Empirical data EQ-5D - - - - - - - - - 11.0 21.0 182.5 146.0 
Empirical data SF-6D - - - 13.7 0.9 - - - - 29.2 51.1 182.5 109.5 
Accetta13 - - - - - - - - - 116.8 167.3 - - 
Balasubramanian14 - - 1.1 - - - - - - 438.0 602.3 - - 
Berkhof15 - 0.9 - - - - 5.5 25.6 25.6 113.2 328.5 - - 
Chuck16 - - - - - - 32.9 47.5 47.5 178.9 232.2 - - 
Coupé17, 18 - 0.9 - - - - 5.5 25.6 25.6 113.2 328.5 - - 
de Bekker-Grob19 0.1 - - 0.1 - 0.9 5.5 25.6 25.6 113.2 511.0 21.9 - 
de Kok4.  
van Rosmalen29 0.1 - - 1.1 - 0.9 5.5 25.6 25.6 113.2 511.0 21.9 - 
Goldhaber-Fiebert21  - - - - - - - - - 116.8 167.3 - - 
Karnon24 - - - 9.0 18.0 - - - - 1460.0 1460.0 - - 
Kitchener26 - - 14.6 - - - 40.2 43.8 40.2 438.0 767.5 - - 
Kitchener (Simonella)22 1.2 9.7 - - - 10.1 10.1 10.8 10.8 438.0 767.5 - - 
Kulasingam27 - - 0.9 - - - - - - 273.8 821.3 - - 
Accetta, Chuck and Goldhaber-Fiebert: Duration health states unknown, assumed 1 year; Chuck: Assumed per invasive stage: 1 year without treatment and 1 year with 
treatment, total duration 2 years; de Kok: Assumed ‘duration since last test' in case of triage testis 6 months; Karnon: Based on 'This mortality is based on an average life 
expectancy with invasive cancer present in an unscreened population of approximately 10 years', we assumed a duration of 10 years for 'remainder of lifetime'; Kitchener: 
Similar durations assumed for cancer as in ‘Kitchener_Simonella’; Kulasingam: Only QoL loss due to cancer treatment (duration 5 years) included.
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Table 2.  Quality of life based utility scores, obtained with SF-6D and EQ-5D, Dutch questionnaire 
study. 
 
Stage Assessments SF-6D EQ-5D Paired t-test 
  (0-1, SD) CI (mean 
±1.96SE) 
(0-1, SD) CI (mean 
±1.96SE) 
p-value 
Reference 
1. General 
population 
1. Between 
screening rounds 
0.83 (0.13) 0.82-0.84 0.86 (0.20) 0.85-0.88 <0.001 
Subgroup: 
screening ages (30-
60 years) 
1. Between 
screening rounds 
0.84 (0.12) 0.83-0.85 0.88 (0.19) 0.86-0.89 <0.001 
Screening  
2. Invited for 
screening 
1. At invitation 0.84 (0.10) 0.84-0.85 0.89 (0.19) 0.88-0.90 <0.001 
Subgroup:  
Screen participants 
1. At invitation 0.84 (0.10) 0.84-0.85 0.89 (0.19) 0.88-0.91 <0.001 
2. After Pap test 0.85 (0.10) 0.85-0.86 0.90 (0.18) 0.89-0.91 <0.001 
3. After Pap test 
result  
0.86 (0.11) 0.85-0.87 0.91 (0.17) 0.90-0.92 <0.001 
Triage 
3. Receiving a 
repeat Pap test 
after BMD1. result 
1. 6-24 months after 
BMD1. Pap test 
0.80 (0.13) 0.79-0.82 0.87 (0.21) 0.84-0.89 <0.001 
Subgroup: NOT 
(yet) referred for 
colposcopy  
1. 6-24 months after 
BMD Pap test 
0.81 (0.12) 0.79-0.83 0.88 (0.21) 0.84-0.91 <0.001 
Referral for colposcopy 
4. Initial six months 
following referral 
for colposcopy 
1. Shortly after 
suspicious Pap test 
0.81 (0.10) 0.79-0.83 0.91 (0.13) 0.89-0.94 <0.001 
2. At 1 month f-up 0.82 (0.12) 0.79-0.84 0.89 (0.18) 0.86-0.93 <0.001 
3. At 3 months f-up 0.82 (0.10) 0.80-0.85 0.92 (0.17) 0.89-0.95 <0.001 
4. At 6 months f-up 0.83 (0.12) 0.81-0.86 0.91 (0.20) 0.87-0.95 <0.001 
5. 6-35 months 
following referral 
for colposcopy. 
1. 6-35 months after 
treatment of CIN 
0.83 (0.11)  0.80-0.85 0.91 (0.15) 0.88-0.94 <0.001 
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(Follow up) Table 2.   Quality of life based utility scores, obtained with SF-6D and EQ-5D, Dutch 
questionnaire study. 
 
 
Cervical cancer 
6. Diagnosed with 
cervical cancer: 
FIGO2. 1A&1B 
1. After diagnosis  0.73 (0.13) 0.69-0.77 0.79 (0.21) 0.73-0.85 0.004 
2. At 3 months f-up 0.75 (0.14) 0.70-0.79 0.81 (0.14) 0.77-0.85 0.001 
3. At 6 months f-up 0.76 (0.15) 0.71-0.81 0.82 (0.21) 0.76-0.89 0.031 
4. At 12 months f-up 0.81 (0.13) 0.77-0.85 0.87 (0.13) 0.83-0.91 0.016 
Diagnosed with 
cervical cancer: 
FIGO2. 2+  
1. After diagnosis  0.71 (0.18) 0.62-0.80 0.72 (0.34) 0.55-0.89 0.939 
2. At 3 months f-up 0.63 (0.11) 0.57-0.70 0.63 (0.31) 0.46-0.80 0.628 
3. At 6 months f-up 0.71 (0.13) 0.64-0.79 0.74 (0.24) 0.61-0.87 0.621 
4. At 12 months f-up 0.75 (0.19) 0.63-0.87 0.73 (0.38) 0.51-0.94 0.603 
7. Tumorfree, 2-10 
years after 
diagnosis 
1. Disease free  0.80 (0.14) 0.79-0.82 0.82 (0.25) 0.79-0.85 0.007 
8. Having advanced 
cancer 
1. Last year of life 
Breast cancer 
Lung cancer 
2. Last three months 
of life 
Breast cancer  
Lung cancer 
 
- 
 
- 
 
0.36 (0.37) 
0.11 (0.38) 
 
 
0.13 (0.39) 
0.10 (0.36) 
 
0.33-0.40 
0.02-0.21 
 
 
0.08-0.18 
-0.01-0.21 
 
- 
1.BMD=borderline or mild dyskaryosis;2.FIGO= International Federation of Gynecology and Obstetrics; f-up 
relates to follow-up in terms of timing of questionnaire assessments
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Table 3. Preferred screening strategy at a threshold of €20,000 and €50,000 per QALY gained (3% 
discounting) by different sources (i.e. literature and empirical data) of QoL assumptions. Costs and 
QALYs gained presented are absolute, compared to no screening. 
 
Threshold QoL assumptions based on  Primary test 
Start 
age 
Number 
of tests 
Interval 
(years) 
Costs 
(€, x1000) 
QALYs 
gained  ICER (€) 
€2
0,
00
0 
pe
r Q
AL
Y 
ga
in
ed
 
Empirical data EQ-5D HPV 30 4 6 369 63 17,857 
Empirical data SF-6D Cytology 32 5 5 409 63 19,963 
Accetta13 HPV 30 4 6 369 62 18,007 
Balasubramanian14 HPV 30 4 6 369 70 16,350 
Berkhof15 HPV 30 4 6 369 60 18,901 
Chuck16 HPV 30 4 6 369 57 20,420 
Coupe17, 18 HPV 30 4 6 369 60 18,901 
de Bekker-Grob19 HPV 30 4 6 369 62 18,844 
de Kok4, van Rosmalen29 HPV 30 4 6 369 62 19,220 
Goldhaber-Fiebert21 HPV 30 4 6 369 62 18,007 
Karnon24 Cytology 30 6 4 472 89 17,151 
Kitchener26 Cytology 32 4 5 288 56 16,099 
Kitchener (SImonella)22 HPV 32 3 6 252 42 16,100 
Kulasingam27 HPV 30 5 6 520 79 19,706 
€5
0,
00
0 
pe
r Q
AL
Y 
ga
in
ed
 
Empirical data EQ-5D HPV 27 9 5 1,074 84 47,378 
Empirical data SF-6D Cytology 27 10 4 931 79 47,739 
Accetta13 HPV 27 9 5 1,074 83 47,977 
Balasubramanian14 HPV 27 9 5 1,074 92 41,426 
Berkhof15 HPV 30 7 6 833 75 43,015 
Chuck16 HPV 30 7 6 833 70 48,966 
Coupe17, 18 HPV 30 7 6 833 75 43,015 
de Bekker-Grob19 HPV 27 8 5 921 78 49,879 
de Kok4, van Rosmalen29 HPV 30 7 6 833 75 46,202 
Goldhaber-Fiebert21 HPV 27 9 5 1,074 83 47,977 
Karnon24 Cytology 30 10 4 992 107 41,144 
Kitchener26 Cytology 27 7 5 586 66 39,120 
Kitchener (SImonella)22 HPV 32 3 6 252 42 16,100 
Kulasingam27 HPV 27 9 5 1,074 95 40,037 
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Figure legends 
 
Figure 1. Utilities measured by the SF-6D and EQ-5D questionnaire per stage in the 
screening and follow up process. Dutch questionnaire study. 
 
Figure 2. Net costs and health effects (compared to no screening) of the efficient screening 
programmes for the fourteen different QADL-sets, for a cohort of 100,000 unvaccinated women, for 
the period from 2011 onwards. Costs and effects discounted with 3% towards year 2011. Each point 
corresponds with a screening policy on the efficient frontier.  Black marker points represent the 
policy at the €20,000 (left-side on the frontier) and €50,000 (right-side at the frontier) per quality-
adjusted life year (QALY) gained threshold (see table 3). 
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APPENDIX ‘Quality of life assumptions determine which cervical cancer screening strategies are 
cost-effective’ 
 
This appendix gives a description of the data-collection procedures and the background 
characteristics of the participants  of the questionnaire study (pages 1-3), summarized in 
Appendix Tables 1 and 2. Furthermore, Appendix Table 3 shows the assumed utilities in 
included published cost-effectiveness analyses (CEAs) per health stage. Table 4 presents the 
sources of the utility values used in the different CEAs. Finally, a description of the model 
and an overview of the input used for the cost-effectiveness calculations is given (Appendix 
Table 5). 
 
The questionnaire study 
 
In the Netherlands, at time of the questionnaire study, women aged 30–60 years, were 
invited every 5 years to attend cytological screening free of charge. Nationally in 2014, the 
5-years coverage was 77%.1 Of the women screened for cervical cancer, 94.3% had normal 
test results and 1.7% of Pap tests were of inadequate quality requiring repeat tests. In 3.2% 
test results were borderline or mildly dyskaryotic (BMD, Pap 2/3a1), and in 0.8% high-grade 
cytological abnormalities, including moderately dyskaryotic (Pap 3a2) or worse, were 
found.1  
 
Following the screening protocol, women with borderline or mildly dyskaryotic results 
(Pap2/3a1) were advised to have follow-up Pap tests with their general practitioner.2 If 
follow-up tests were again borderline or mildly dyskaryotic, these women were referred for 
colposcopy. Women with high-grade cytological abnormalities (Pap 3a2 or worse) were 
immediately referred for colposcopy and punch biopsy. 
 
Study groups in the questionnaire study 
 
1. Reference population 
To include a reference group from the general population 1,800 randomly selected 
women (aged 30–70 years, stratified in 10-year age groups) were sent a questionnaire 
through the regional screening organization in Maastricht (The Netherlands) between 
April and June 2006. 835 women completed the questionnaire (response rate 46%). 
 
2. Screening 
A random sample of 2,300 women, aged 30-60 years, was obtained at the moment of 
delivery of the screening invitation from the regional screening organization in 
Maastricht (The Netherlands) between April and August 2006 18. Sampled women 
received a letter, a questionnaire, and a consent form. Of the 2,300 addressed women 
2 
1,551 had the screening test. 1,023 women completed the baseline questionnaire 
(response rate 44%). At a group level we know that 924 women who completed the 
first questionnaire had the screening test, at an individual level this is known to us 
about 905 women. The response rate among screen participants was 60% (924/1,551 
screen participants). 
Subgroup of screen participants: Women who gave consent to participate in our 
questionnaire study and who had a screening test within four months following their 
invitation were sent a second questionnaire following their Pap test and a third one 
attached to the letter informing them about their test results.  
 
3. Triage 
Between April and August 2006 we conducted a cross-sectional survey in cooperation 
with the regional screening organization in Maastricht (The Netherlands) 2. Five 
hundred and fifty women who participated in the Dutch cervical cancer-screening 
programme with a borderline (Pap 2) or mildly (Pap 3a1) dyskaryotic (BMD) Pap smear 
result in the previous 6–24 months were sent a questionnaire. 270 women completed 
the questionnaire (response rate 49%). 
 
REFERRAL FOR COLOSCOPY 
 
4. Undergoing gynecological evaluation 
Between February 2006 and April 2008 a prospective longitudinal cohort study was  
conducted in two Dutch hospitals 19, aiming to include all consecutive women who 
were referred for gynecological evaluation because of abnormal Pap test results in the 
national screening program. These women were sent a letter, asking for informed 
consent to participate in the study. This involved completion of four questionnaires in 
the course of six months. Women were also asked for permission to consult their 
patient files and/or the gynecologist about their colposcopy follow-up. If the patient 
file or the information of the gynecologist showed that women were ineligible, e.g. 
since they had not been referred in the context of the screening program, women 
were excluded. 
5. Treated for CIN 
From February 2006 onwards in two Dutch hospitals women who had been referred 
for gynaecological evaluation 6 to 35 months earlier and had been treated for a 
precursor of cervical cancer were identified in the medical files and approached with a 
letter and a questionnaire. 81 women completed the questionnaire (response rate 49 
%). 
 
3 
 
CERVICAL CANCER 
6. Diagnosed with cervical cancer 
Between March 2006 and April 2008 a prospective longitudinal cohort study was 
conducted in four Dutch hospitals, aiming to include all consecutive women who were 
diagnosed with cervical cancer. These women were sent a letter, asking for informed 
consent to participate in the study. This involved completion of four questionnaires in 
the course of 12 months. Women were also asked for permission to consult their 
patient files and/or the gynaecologist about their treatment.  
7. Tumorfree 2-10 years after diagnosis 
In cooperation with the Eindhoven regional cancer registry and all gynaecologic 
oncology departments in the region, we conducted a population-based cross-sectional 
survey17. We identified all women who had been diagnosed with cervical cancer 
between January 1995 and December 2003 (n = 691). Women who had died could be 
excluded through linkage with the Central Bureau for Genealogy that collects data for 
all deceased Dutch citizens. We identified 444 women (64%) who were still alive on 
January 31, 2006. Of this group, 8 women were not contacted as advised by their 
physician, e.g., because of serious (mental) illness, and 15 addresses could not be 
verified. The remaining 421 survivors were sent a questionnaire by their (former) 
gynaecologists. In the accompanying letter, the women were asked to complete the 
questionnaire and were informed that by returning the completed questionnaire, they 
consented to linkage of the questionnaire data with their disease history as registered 
by the cancer registry. 291 women completed the questionnaire (response rate 69%). 
For this paper we excluded women who were known to have recurrence at time of 
questionnaire completion (n=6). 
8. Having advanced cancer 
For logistic reasons we were not able to include women with advanced cancer in our 
study. For this patient group we opted for using data that were obtained in another 
study context15,16. Data were available for women with advanced stages of breast 
(n=340) and lung cancer (n=44) in their last year of life. 
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Appendix Table 1 Overview of study groups and timing of assessments  
 
STAGE Description of groups (n) Inclusion site(s) Utility assessments 
Reference   
1. General population Women who had not been invited for 
cervical cancer screening in the previous 2 
years, n= 835 
Screening 
organisation 
1. In between screening rounds 
Subgroup: screening ages (30-
60 years) 
Women eligible for cervical cancer 
screening, n=612 
 1. In between screening rounds 
Screening     
2. Invited for cervical cancer 
screening  
Women invited for the next screening 
round, n=1,023 
Screening 
organisation 
1. At moment of invitation 
Subgroup: screen participants Women who had a Pap test following the 
invitation 
 1. Before screening (n= 905). 
2. After screening (n=802) 
3. After test result (n=843) 
Triage    
3. Receiving a repeat Pap test 
after BMD1. result 
Women who were advised to have a repeat 
Pap test because of a BMD Pap test, n=270 
Screening 
organisation 
1. 6-24 months after BMD Pap 
test  result 
Subgroup: not (yet) referred 
for colposcopy 
n=159  1. 6-24 months after BMD Pap 
test  result 
Referral for colposcopy   
4. Initial six months following 
referral for colposcopy 
Women who underwent a gynaecological 
evaluation after abnormal Pap results, 
n=132 
Two gynaecology 
departments of 
general hospitals  
1. Shortly after suspicious test 
result  (n=132); 
2. At 1 month follow-up* 
(n=114); 
3. At 3 months follow-up* 
(n=110); 
 4. At 6 months follow-up* 
(n=108) 
5. 6-35 months following 
referral for colposcopy. 
Women treated for CIN2., n=81 Two gynaecology 
departments of 
general hospitals 
1. 6-35 months after treatment 
of     CIN 
Cervical cancer   
6. Diagnosed with cervical 
cancer  
Subdivided into ‘FIGO3. 1a & 
1b’ and ‘FIGO3.2+’ 
 
Women who were recently diagnosed with 
invasive cervical cancer, n=77 
Four gynaecology 
departments of 
general hospitals 
1. Shortly after diagnosis (n=77) 
2. At 3 months follow-up* (n=66) 
3. At 6 months follow-up* (n=64) 
4. At 12 months follow-up* 
(n=62) 
7. Tumorfree 2-10 years after 
diagnosis 
Women who were treated for cervical 
cancer, n=285 
One cancer registry 
region (17 hospitals) 
1. 2-10 years after cervical cancer 
diagnosis and treatment 
8. Having advanced cancer Women with advanced cancer 
Breast cancer, n=340 
Lung cancer, n=44 
Secondary data 
analysis 
1. Last 12 months of life  
2. Last 3 months of life 
1.BMD=borderline of mild dyskaryosis; 2.CIN = cervical intraepithelial neoplasia; 3.FIGO= International 
Federation of Gynecology and Obstetrics; follow-up refers to timing of questionnaire assessment
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Appendix Table 2 Background characteristics of the participants 
Stage N 
Education 1. (N (%)) Employment status (N (%)) Marital status (N (%)) Age 
Low Medium High Paid job Housewife/unpaid job/student No job Retired 
Married/ 
cohabiting 
Living without 
partner Mean (SD) range 
Reference  
1. General population 835 273 (35%) 358 (46%) 150 (19%)  372 (51%) 238 (32%) 52   (7%) 72 (10%) 654 (78%) 181 (22%) 51.8 (11.4) 27-72 
Subgroup: screening ages (30-
60 years) 
612 154 (27%) 296 (51%) 129 (22%) 358 (67%) 125 (23%) 44 (8%) 9 (2%) 499 (82%) 113 (19%) 47.2 (8.9) 27-62 
Screening   
2. Invited for cervical cancer 
screening 1,023 209 (23%) 457 (49%) 263 (28%) 608 (68%) 201 (22%) 74 (8%) 16 (2%) 807 (79%) 211 (21%) 45.1 (9.4) 29-60 
Subgroup: screen participants 905 181 (22%) 410 (50%) 227 (28%) 541 (68%) 178 (22%) 64 (8%) 14 (2%) 715 (79%) 185 (21%) 45.3 (9.4) 29-60 
Triage 
3. Receiving a repeat Pap test 
after BMD2. result 270 39 (16%) 132 (56%) 67 (28%) 168 (74%) 34 (15%) 26 (11%) - 188 (74%) 65 (26%) 43.0 (7.9) 30-62 
Subgroup: NOT yet referred 
for colposcopy 159 19 (14%) 87 (62%) 35 (25%) 100 (74%) 25 (18%) 11 (8%) - 113 (75%) 38 (25%) 42.6 (7.7) 30-62 
Referral for colposcopy 
4. Initial six months following 
referral for colposcopy 
114 17 (16%) 67 (63%) 22 (21%) 82 (83%) 11 (11%) 6 (6%) - 81 (74%) 29 (26%) 40.8 (8.4) 29-60 
5. 6-35 months following 
referral for colposcopy. 81 14 (18%) 46 (58%) 20 (25%) 61 (82%) 9 (12%) 4 (5%) - 63 (78%) 18 (22%) 41.3 (8.0) 30-62 
Cervical cancer 
6. Diagnosed with cervical 
cancer: FIGO4. 1A&1B 
47 7 (18%) 27 (68%) 6 (15%) 28 (72%) 7 (18%) 3 (8%) 1 (3%) 27 (66%) 14 (34%) 42.8 (9.0) 29-72 
Diagnosed with cervical 
cancer: FIGO4. 2+  
16 2 (18%) 8 (73%) 1 (9%) 7 (70%) 1 (10%) 1 (10%) 1 (10%) 7 (58%) 5 (42%) 46.7 (15.4) 30-89 
7. Tumorfree, 2-10 years after 
diagnosis 
285 114 (44%) 115 (45%) 29 (11%) 94 (41%) 83 (37%) 28 (12%) 22 (10%) 184 (67%) 91 (33%) 52.7 (13.6) 31-88 
8. Having advanced cancer5 340 (breast cancer) 
44 (lung cancer) 
59.6 (12.5) 
63.3 (10.1) 
32-89 
45-87 
1. Educational level was classified as low (primary school or lower technical education), intermediate, or high (college/university degree); 2. BMD=borderline of mild 
dyskaryosis; 3. CIN = cervical intraepithelial neoplasia; 4. FIGO= International Federation of Gynecology and Obstetrics; 5. these data were collected by others, with 
information about age being available for the whole dataset, and data on employment status being available for a subset of 61 participants
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The literature review 
 
To collect the utilities that have been used so far, we reviewed the literature for CEAs of 
cervical cancer screening published between 2003 and 2015. We used the following search 
query in Pubmed: 
 
((("cost-benefit analysis"[MeSH Terms] OR ("cost-benefit"[All Fields] AND "analysis"[All Fields]) OR "cost-benefit 
analysis"[All Fields] OR ("cost"[All Fields] AND "effectiveness"[All Fields] AND "analysis"[All Fields]) OR "cost 
effectiveness analysis"[All Fields]) AND (("uterine cervical neoplasms"[MeSH Terms] OR ("uterine"[All Fields] 
AND "cervical"[All Fields] AND "neoplasms"[All Fields]) OR "uterine cervical neoplasms"[All Fields] OR 
("cervical"[All Fields] AND "cancer"[All Fields]) OR "cervical cancer"[All Fields]) AND ("diagnosis"[Subheading] 
OR "diagnosis"[All Fields] OR "screening"[All Fields] OR "mass screening"[MeSH Terms] OR ("mass"[All Fields] 
AND "screening"[All Fields]) OR "mass screening"[All Fields] OR "screening"[All Fields] OR "early detection of 
cancer"[MeSH Terms] OR ("early"[All Fields] AND "detection"[All Fields] AND "cancer"[All Fields]) OR "early 
detection of cancer"[All Fields]))) AND ("quality-adjusted life years"[MeSH Terms] OR ("quality-adjusted"[All 
Fields] AND "life"[All Fields] AND "years"[All Fields]) OR "quality-adjusted life years"[All Fields] OR "qaly"[All 
Fields])) AND ("2003/01/01"[PDAT] : "2015/12/31"[PDAT]) 
 
Appendix Table 3 shows the assumed utilities in included published CEAs per health stage, as 
well as the source of the utilities reported in the specific CEAs. Appendix Table 4 presents 
the original sources of assumed utilities. We found that all CEAs finally refer to 12 different 
sources, published between 1991 and 2012: 
 
• de Haes et al. Int J Cancer 1991 
• Fryback DG, et al. Med Decis Making 1993 
• Wolfson MC. Health Rep 1996    
• Gold MR, et al.  Med Care.1998 
• Stratton et al. Vaccines for the 21th century: A tool for decision making. Washington: 
National Academy Press, 2000 
• Conference abstract: Myers ER. 21st International Papillomavirus Conference Mexico 
City, 2004. 
• Maissi E, et al Br J Cancer 2005 
• Hanmer J, et al. Med Decis Making 2006 
• Insinga et al. Med Decis Making 2007 
• Conference abstract: Insinga RP, et al. 22nd International Papillomavirus Conference 
Vancouver, Canada, 2007. 
• Thesis: Simonella LM. NSW: University of Sydney, 2012. 
• Website: Center for the Evaluation of value and Risk in Health. Catalog of Preference 
Scores: the CEA Registry. Boston, MA: Tufts New England Medical Center. 
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Appendix Table 3. Assumed utilities in included published CEAs per health stage (in case of two utility values for one stage, the first utility value represents the short term 
effect and the second value represents the long term effect) 
 
 
Induced by screening: screening and pre-invasive health states Prevented by screening: invasive cancer health states Sources 
reported 
for utility 
values 
Prim. 
screens 
Pos. 
prim. 
screens 
False-
pos. 
prim. 
screens 
Triage 
tests 
Referr
als for 
colpos
copy 
False-
pos. 
Refer
ral 
CIN1 CIN2 CIN3 FIGO 1 FIGO 2+ Palliative 
phase 
Survivors 
Accetta3 0 0 0 0 0 0 0 0 0 0.68 0.56/0.48 0 0 
4 
Balasubramanian5 0 0 0.98 0 0 0 0 0 0 0.76 0.67 0 0 
6 
Berkhof7 0 0.97 0 0 0 0 0.97 0.93 0.93 0.65/0.97 0.55/0.85 0 0 
8-10 
Chuck11 0 0 0 0 0 0 0.91 0.87 0.87 0.65/0.86 0.67/0.83
1 0 0 12 
Coupe13, 14 0 0.995 0 0 0 0 0.97 0.93 0.93 0.65/0.97 0.55/0.85 0 0 
8, 10 
de Bekker-Grob15 0 0 0 0.97 0.994 0.994 0.97 0.93 0.93 0.938 0.72 0.288 0 
8, 16 
de Kok17. van Rosmalen18 0 0 0 0.995 0.994 0.994 0.97 0.93 0.93 0.938 0.72 0.288 0 
8, 10, 16 
Goldhaber-Fiebert4 0 0 0 0 0 0 0 0 0 0.68 0.56
2 0 0 19-21 
Karnon22 0 0 0 0.975
3 0.953 0 0 0 0 0.6 0.6 0 0  
Kitchener23 0 0 0.96 0 0 0 0.89 0.88 0.89 0.76 0.67
4 0 0 6, 8, 10, 21, 24-26 
Kitchener (Simonella)27 0.997 0.974 0 0 0 0.972 0.972 0.970 0.970 0.76 0.67
4 0 0 10, 28, 29 
Kulasingam30 0 0 0.97 0 0 0 0 0 0 0.85 0.55 0 0 
8, 21 
1 Represents the utility values for FIGO 2. assumptions for other stages are: FIGO3 - 0.56/0.83. FIGO4 - 0.48/0.63 
2 Represents utility value for FIGO2/3. for FIGO 4 a value of 0.48 is assumed. 
3 Average base case utility value (the study uses two other base case utility values as well: 0.95 and 0.98 for triage. 0.9 and 0.97 for colposcopy 
4 Represents the utility values for FIGO 2. assumptions for other stages are: FIGO3 - 0.56. FIGO 4 - 0.48 
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Appendix Table 4. Literature sources of assumed utilities in included published CEAs. Gray shaded sources are the original utility studies.   
  Sources reported for utility values Sources of sources 
1 Accetta3 Goldhaber-Fiebert JD, et al. J Natl Cancer Inst 20084 See 8 
2 Balasubramanian5 Myers ER. 21st IPV Conference Mexico City, 2004. 6  
3 Berkhof7 Mandelblatt JS,et al JAMA 20028 Gold MR, et al.  Med Care.199831 
  Maissi E, et al Br J Cancer 20059  
  Goldie SJ, et al. J Natl Cancer Inst 200410 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
4 Chuck11 Krahn M, et al. Canadian Agency for Drugs and Technologies in 
Health, 2008. 12 
Myers ER. 21st IPV Conference Mexico City, 2004. 6 
   Goldie SJ et al. Int J Cancer 2003*33 
   Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
   Mandelblatt et al. JAMA 1988*34 
5 Coupe13, 14 Mandelblatt JS, et al JAMA 20028 Gold MR, et al.  Med Care.199831 
  Goldie SJ, et al. J Natl Cancer Inst 200410 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
6 de Bekker-Grob15 Mandelblatt JS,et al. JAMA 20028 Gold MR, et al.  Med Care.199831 
  Thesis: van Ballegooijen M. Erasmus University Rotterdam, 1998. 16 de Haes et al. Int J Cancer 199135 
7 de Kok17van Rosmalen18 Mandelblatt JS, et al. JAMA 20028 Gold MR, et al.  Med Care.199831 
  Goldie SJ, et al. J Natl Cancer Inst 200410 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
  Thesis: van Ballegooijen M. Erasmus University Rotterdam, 1998. 16 de Haes et al. Int J Cancer 199135 
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Appendix Table 4 (continued). Literature sources of assumed utilities in included published CEAs. Gray shaded sources are the original utility studies 
 
8 Goldhaber-Fiebert4 Hanmer J, et al. Med Decis Making 200619  
  Website: Center for the Evaluation of value and Risk in Health. 
Boston, MA: Tufts New England Medical Center.20 
 
  Kim JJ, et al. JAMA 200221 Gold MR, et al. Med Care.199831 
   Fryback DG, et al. Med Decis Making 1993 
9 Karnon22 Not reported  
10 Kitchener23 Myers ER. 21st IPV Conference Mexico City, 2004. 6  
  Mandelblatt JS, et al. JAMA 20028 Gold MR, et al.  Med Care.199831 
  Goldie SJ, et al. J Natl Cancer Inst 200410 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
  Kim JJ, et al. JAMA 200221 Gold MR, et al. Med Care.199831 
   Fryback DG, et al. Med Decis Making 199336 
  Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
 
  Sanders GD, Taira AV. Emerg Infect Dis 200325 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Fryback DG, et al. Med Decis Making 199336 
  Insinga RP, et al. 22nd International Papillomavirus Conference 
Vancouver, Canada, 2007. 26 
 
11 Kitchener (Simonella)27 Goldie SJ, et al. J Natl Cancer Inst 200410 Stratton et al. Vaccines for the 21th century: A tool for decision 
making. Washington: National Academy Press, 200024 
   Wolfson MC. Health Rep 199632 
   Gold MR, et al. Med Care.199831 
  Elbasha EH, et al. Emerg Infect Dis 200728 Gold MR, et al. Med Care.199831 
   Myers ER. 21st IPV Conference Mexico City, 2004. 6 
   Insinga et al. Med Decis Making 200737 
  Thesis: Simonella LM. NSW: University of Sydney, 2012. 29  
12 Kulasingam30 Mandelblatt JS, et al. JAMA 20028 Gold MR, et al.  Med Care.199831 
  Kim JJ, et al. JAMA 200221 Gold MR, et al. Med Care.199831 
   Fryback DG, et al. Med Decis Making 199336 
 
*Sources of sources of sources could not be found 
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Model description for cost-effectiveness calculations 
 
costs and the effects of different programmes were estimated using the microsimulation 
screening analysis (MISCAN) model. In MISCAN a large population is simulated that consists 
of hypothetical (but realistic) individual life histories. If applied to cervical cancer  some 
women will develop high-risk HPV infection(s), cervical neoplasia or cancer. This simulation 
yields an age-specific output of the prevalence of HPV infections and cervical neoplasia, and 
the incidence and the mortality of cervical cancer. This simulated population then 
undergoes simulated (but realistic) screening, which changes some of the life histories. The 
effects of screening can be determined from the changes in the life histories using the 
numbers of events and stages induced or prevented. This approach yields the changes in the 
number of life years, the quality of life and the costs. 
 
Model specifications: demography, epidemiology and natural history 
For this manuscript we simulated the Dutch population at risk for cervical cancer  based on 
demographic and hysterectomy data;38 39 mortality from other causes was estimated using 
the observed age-specific mortality in the Netherlands in 2008.38 The age-specific incidence 
of HPV infections that progress to cervical cancer was calibrated to the age distribution of 
the prescreening mortality in the Netherlands; the latter distribution was corrected for 
cohort effects based on an age–period–cohort analysis.16 The estimated cumulative 
incidence of HPV infections that progress to cervical cancer is 1.06% for women born in the 
period 1939–1948, and 1.48% for women born after 1948; these assumptions have been 
used previously.40 The age-specific incidence of pre-invasive lesions that do not progress to 
cancer was calibrated so that the simulated detection rates of cervical intraepithelial 
neoplasia (CIN) fit the observed CIN detection rates in the Netherlands; the observed 
detection rates were obtained from the Dutch Network and National Database for 
Pathology (PALGA) for the period 1997–2001. Finally, the age-specific incidence of high-risk 
HPV infections that do not progress to CIN was calibrated so that the simulated prevalence 
of all high-risk HPV infections fits the observed high-risk HPV prevalence.41  
In the model, the disease is subdivided into seven sequential stages: high-risk HPV infection 
(low-risk HPV infections are not simulated in the model); three pre-invasive stages (CIN 1, 2 
and 3), and three invasive stages (International Federation of Obstetrics and Gynecology 
staging; FIGO 1A, 1B and 2+). Pre-invasive stages and FIGO 1A cases can only be diagnosed 
by screening, as they are assumed to be asymptomatic, whereas FIGO 1B and 2+ cases can 
also be clinically diagnosed. HPV infections are usually not progressive; in the model, more 
than 90% of HPV infections will clear without resulting in CIN, and most lesions in the pre-
invasive stages regress naturally. For example, in the absence of cervical screening. 
approximately 72% of the CIN 3 lesions in the model would not become cancer, which 
corresponds well with estimates from a retrospective cohort study of women with 
untreated CIN 3.42 In a CIN lesion, a high-risk HPV infection may or may not be present. In 
the model it is assumed that, without an HPV infection, a CIN lesion will not progress to 
cervical cancer. In the invasive stages, all women are assumed to be HPV infected. A woman 
can develop multiple HPV infections and neoplasias in her lifetime, and multiple infections 
and neoplasias can exist at the same time. Weibull probability distributions are used to 
assume variation among women in the durations of the different stages. The inputs on 
stage-specific survival in clinical cases are age specific, and are based on observed survival 
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data and on Dutch mortality-to-incidence ratios from the prescreening period in the 
Netherlands.16  
We used a population model that simulates the life histories of 8 million unvaccinated 
women born between 1939 and 1992; women born before 1939 are too old to attend 
screening after 2011, and women born after 1992 are eligible for HPV vaccination. The 
simulated screening programmes start in 2011 and continue until all women have 
completed their screening programmes. Results of screening practices before 2011, can 
influence the effectiveness of the screening programme after 2011. Therefore, we also 
simulated the last three screening rounds before 2011, based on the assumption that  
screening rounds before 1996 will not affect the screening results after 2011. Information 
on the screening activities before 2011 was obtained from PALGA. 
 
Assumptions for screening and treatment 
In our analyses, we varied the ages at which screening takes place. We considered all 
screening policies with starting ages of 25, 27, 30 or 32 years that comprise at least three 
and at most ten screenings in a woman’s lifetime, and that have an interval of at least 3 
years and at most 10 years; policies that include screenings over the age of 70 years were 
not simulated. 
We assumed that 10% of the population never attends screening and has a three times 
higher background risk (i.e. using the cervical cancer incidence in a situation without 
screening) than the 90% potential attenders. This assumption is based on an analysis of data 
from the start of organised screening.43  We assumed that the potential attenders attend 
80% of all primary screenings. so that the overall attendance rate is 72%; under the base-
case assumptions, follow-up screenings and referrals for colposcopy are always attended. 
The sensitivity of the HPV test (the probability of a positive test result if an HPV infection is 
present) was estimated at 94%, and the sensitivity of cytology was assumed to be 40% for 
CIN 1, 50% for CIN 2, and 75% for CIN 3 and invasive cervical cancer (see Appendix Table 5).7 
The specificity of the HPV test (probability of a negative test for women without high risk 
HPV infections) is assumed to be 100%, and the specificity of cytology (probability of a 
negative test for women without CIN or cancer) is estimated to be 98.5%, based on the 
observed false positive rate of Pap smears in the Dutch screening programme. Several 
screening strategies distinguish between smears read as ASC-US/LSIL (atypical squamous 
cells and low-grade cervical squamous intraepithelial lesions, equivalent to borderline/mild 
dyskaryosis) and smears read as at least HSIL (high-grade cervical squamous intraepithelial 
lesions, equivalent to moderate dyskaryosis). Therefore, the probability of at least HSIL is 
also specified for each disease stage in Appendix Table 5. The detection and the associated 
management (including retreatment, if necessary) of pre-invasive lesions were assumed to 
lead to a 100% cure rate. For screen-detected invasive cancers, the survival was modelled as 
a reduction in the risk of dying from cervical cancer compared with that of dying from 
clinically diagnosed cancer: in the model, detection by screening of an invasive cancer 
results in a reduction of the risk of dying of cervical cancer of 80% (FIGO 1A), 60% (FIGO 1B) 
or 20% (FIGO 2+). 
 
Assumptions for costs 
Appendix Table 5 presents the costs used in the analysis. The estimated costs are based on a 
societal perspective, and are reported in 2010 euros (€). The screening costs include the 
costs for the invitational system and quality assurance, the time and travel costs of the 
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woman being screened, the costs of smear taking, the costs of cytological evaluation, the 
costs of repeat tests after an inadequate test result and the costs of registration in PALGA. 
The diagnosis costs for women referred for colposcopy, the treatment costs for detected 
pre-invasive lesions, the costs of primary treatment for invasive cervical cancer, and the 
costs of treatment and palliative care for advanced cervical cancer were derived from 
previous cost studies performed in the Netherlands.44  
 
Cost-effectiveness analysis 
The costs and the effects of each simulated screening programme are counted for the 
period from 2011 onwards. Future costs and health effects (life years and utility losses) are 
discounted in the base-case analysis towards the year 2011 at a rate of 3%. Programmes 
that are more costly and less effective than other programmes are ruled out as nonefficient 
(i.e. by simple dominance). Programmes that are more costly and less effective than a 
combination of other programmes are also ruled out as non-efficient (i.e. by extended 
dominance). The remaining programmes constitute the frontier of efficient screening 
programmes. The total costs consist of the costs of the invitations (including the costs of the 
invitational system and the quality assurance), the primary and follow-up screenings, the 
treatment of pre-invasive and invasive lesions, and terminal care. We compute the net costs 
of screening as the difference in the total costs between the simulation in which the 
screening programme is implemented and a simulation without cervical screenings after 
2011. The total number of QALYs is the number of years lived by the population minus the 
utility losses associated with attending screening, receiving treatment and having a terminal 
stage of cervical cancer. The number of QALYs gained by screening is the total number of 
QALYs in the simulation with the screening programme, minus the total number of QALYs in 
a simulation without screening after 2011. 
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Appendix Table 5. Model assumptions which are identical for all QoL scenario's: test characteristics and costs 
 
Parameter Value 
Attendance of potential attenders* 80% 
Sensitivity of cytology  
Probability of at least ASCUS (at least triage) for:  
CIN grade I 40% 
CIN grade II 50% 
CIN grade III and cervical cancer 75% 
Probability of at least HSIL (referral for colposcopy) for:  
CIN grade I 4% 
CIN grade II 19% 
CIN grade III and cervical cancer 47% 
Specificity of cytology (CIN grade I or worse)  98.5% 
Sensitivity of HPV test‡ 94% 
Specificity of HPV test§ 100% 
Costs of screening (€)  
Invitation 4.65 
Cytology (first) 60.39 
Cytology (repeat after at least 6 months) 30.27 
HPV-test (first) 62.80 
HPV-test (repeat) 29.00 
Costs of treatment pre-invasive disease (€)  
False positive 279 
CIN1 869 
CIN2 1.287 
CIN3 1.507 
Costs of treatment of invasive cancer (€)  
FIGO 1A 4.935 
FIGO 1B 11.703 
FIGO 2+ 10.773 
Terminal care 26.209 
*The potential attenders consist of 90% of the female population; the remaining women are assumed to never 
attend screening. 
‡Probability to detect an HPV infection. regardless of whether a CIN lesion or cancer is present. 
§A possible lack of specificity was modelled by including fast-clearing HPV infections. 
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